{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T05:45:23Z","timestamp":1792907123636,"version":"4.5.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>In patients with hormone receptor-positive (HR+)\/premenopausal breast cancer, luteinizing hormone-releasing hormone analogs (LHRHas) are used as standard endocrine treatment. Based on previous clinical studies, 1-month formulations are recommended in most breast cancer treatment guidelines, but long-acting formulations facilitate reductions in side effects and patient discomfort caused by frequent administration. However, few efficacy studies have been conducted on 6-month formulations. Therefore, this study aimed to evaluate the efficacy of 6-month formulations of LHRHas.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective study was conducted from January 2018 to December 2019 and involved premenopausal patients with HR+ breast cancer administered 6-month LHRHas as adjuvant treatment after surgery, and those previously administered chemotherapy or other LHRHa types were excluded. Patients\u2019 estradiol (E2) and follicle-stimulating hormone (FSH) levels were measured before surgery, and their E2 levels were also measured at 3, 6, 12, 18, and 24 months at periodic postsurgical examinations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 228 patients were included, and the median patient age was 44 (range, 25\u201354) years. The mean serum E2 and FSH levels before surgery were 69.7 (range, 4\u2013683) pg\/mL and 7.3 (range, 0.4\u201388.9) mIU\/mL, respectively, whereas the mean serum E2 level monitored at intervals during the 6-month LHRHa administration was 5.5 (range, 4.0\u201352) pg\/mL. No women menstruated during the follow-up period after the LHRHas administration, and the E2 levels were less than 30 pg\/mL in all patients except one.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The 6-month LHRHa formulation adequately suppressed ovarian function in premenopausal patients with HR+ breast cancer. This indicates that long-acting LHRHas can be effectively used for patient convenience and that there is high compliance with long-term use.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.665426","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T07:53:09Z","timestamp":1619596389000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Effectiveness of a 6-Month 22.5-mg Leuprolide Acetate Depot Formulation With Tamoxifen for Postoperative Premenopausal Estrogen Suppression in Hormone Receptor-Positive Breast Cancer"],"prefix":"10.3389","volume":"11","author":[{"given":"Zhen-Yu","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heejeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jongwon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Il Yong","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jisun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saebyeol","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung-Ho","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Bae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Ho","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyungyub","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sei-Hyun","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BeomSeok","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12885-018-5186-8","article-title":"Estrogen Receptor Signaling Regulates the Expression of the Breast Tumor Kinase in Breast Cancer Cells","volume":"19","author":"Miah","year":"2019","journal-title":"BMC Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01160","article-title":"Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update","volume":"37","author":"Burstein","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.4048\/jbc.2016.19.4.341","article-title":"Role of Ovarian Function Suppression in Premenopausal Women With Early Breast Cancer","volume":"19","author":"Park","year":"2016","journal-title":"J Breast Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1677\/erc.1.00777","article-title":"Gonadotropin-Releasing Hormone and Its Receptor in Normal and Malignant Cells","volume":"11","author":"Harrison","year":"2004","journal-title":"Endocr Relat Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"977","DOI":"10.6004\/jnccn.2019.0038","article-title":"Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Swarm","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1159\/000499931","article-title":"St. Gallen\/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment","volume":"14","author":"Balic","year":"2019","journal-title":"Breast Care (Basel)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.09.112","article-title":"Randomized Adjuvant Trial of Tamoxifen and Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil: Evidence for the Superiority of Treatment With Endocrine Blockade in Premenopausal Patients With Hormone-Responsive Breast Cancer\u2014Austrian Breast and Colorectal Cancer Study Group Trial 5","volume":"20","author":"Jakesz","year":"2002","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.05.042","article-title":"Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy in Premenopausal Patients With Node-Positive Breast Cancer: The Zoladex Early Breast Cancer Research Association Study","volume":"20","author":"Jonat","year":"2002","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.064","article-title":"Quality of Life in Goserelin-Treated Versus Cyclophosphamide + Methotrexate + Fluorouracil-Treated Premenopausal and Perimenopausal Patients With Node-Positive, Early Breast Cancer: The Zoladex Early Breast Cancer Research Association Trialists Group","volume":"21","author":"de Haes","year":"2003","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s0959-8049<(>03<)>00392-7","article-title":"Survival Analyses From the ZEBRA Study. Goserelin (Zoladex\u2122) Versus CMF in Premenopausal Women With Node-Positive Breast Cancer","volume":"39","author":"Kaufmann","year":"2003","journal-title":"Eur J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.8534","article-title":"Leuprorelin Acetate Every-3-Months Depot Versus Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Treatment in Premenopausal Patients With Node-Positive Breast Cancer: The TABLE Study","volume":"25","author":"Schmid","year":"2007","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2009.01.016","article-title":"Short Term Results From GHRH Analogue Use in Pre-Menopausal Breast Cancer in Korea","volume":"35","author":"Kim","year":"2009","journal-title":"Eur J Surg Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2015.444","article-title":"Survival Outcome of Combined Gnrh Agonist and Tamoxifen is Comparable to That of Sequential Adriamycin and Cyclophosphamide Chemotherapy Plus Tamoxifen in Premenopausal Patients With Lymph-Node-Negative, Hormone-Responsive, HER2-Negative, T1-T2 Breast Cancer","volume":"48","author":"Sohn","year":"2016","journal-title":"Cancer Res Treat"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803164","article-title":"Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer","volume":"379","author":"Francis","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.502","article-title":"Role of Adding Ovarian Function Suppression to Tamoxifen in Young Women With Hormone-Sensitive Breast Cancer Who Remain Premenopausal or Resume Menstruation After Chemotherapy: The ASTRRA Study","volume":"36","author":"Noh","year":"2018","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-010-1332-y","article-title":"Monthly Versus 3-Monthly Goserelin Acetate Treatment in Pre-Menopausal Patients With Estrogen Receptor-Positive Early Breast Cancer","volume":"126","author":"Masuda","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-015-0637-4","article-title":"Phase 3, Open-Label, Randomized Study Comparing 3-Monthly With Monthly Goserelin in Pre-Menopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer","volume":"23","author":"Noguchi","year":"2016","journal-title":"Breast Cancer (Auckl)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-016-0691-6","article-title":"Efficacy and Safety of Leuprorelin Acetate 6-Month Depot, TAP-144-SR (6M), in Combination With Tamoxifen in Postoperative, Premenopausal Patients With Hormone Receptor-Positive Breast Cancer: A Phase III, Randomized, Open-Label, Parallel-Group Comparative Study","volume":"24","author":"Kurebayashi","year":"2017","journal-title":"Breast Cancer (Auckl)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2018.04.005","article-title":"Efficacy of Different Leuprolide Administration Schedules in Premenopausal Breast Cancer: A Retrospective Review","volume":"18","author":"Kendzierski","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1097\/GME.0000000000001568","article-title":"Baseline Estrogen Levels in Postmenopausal Women Participating in the MAP.3 Breast Cancer Chemoprevention Trial","volume":"27","author":"Richardson","year":"2020","journal-title":"Menopause"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/00042192-200512020-00005","article-title":"Defining Menopause Status: Creation of a New Definition to Identify the Early Changes of the Menopausal Transition","volume":"12","author":"Gracia","year":"2005","journal-title":"Menopause"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.5.8510","article-title":"Negative Feedback Effects of Gonadal Steroids are Preserved With Aging in Postmenopausal Women","volume":"87","author":"Gill","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.gendis.2018.05.001","article-title":"Breast Cancer Development and Progression: Risk Factors, Cancer Stem Cells, Signaling Pathways, Genomics, and Molecular Pathogenesis","volume":"5","author":"Feng","year":"2018","journal-title":"Genes Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.19.1433","article-title":"Oophorectomy for Breast Cancer: History Revisited","volume":"94","author":"Love","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2019.1913","article-title":"Survival Outcome of Combined Gnrh Agonist and Tamoxifen is Comparable to That of Sequential Adriamycin and Cyclophosphamide Chemotherapy Plus Tamoxifen in Premenopausal Patients With Early Breast Cancer","volume":"11","author":"Sa-Nguanraksa","year":"2019","journal-title":"Mol Clin Oncol"},{"key":"B26","article-title":"Endocrinology Adult and Pediatric: Reproductive Endocrinology","volume-title":"Health Sciences","author":"Jameson","year":"2013"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S44855","article-title":"Leuprolide Acetate 1-, 3- and 6-Monthly Depot Formulations in Androgen Deprivation Therapy for Prostate Cancer in Nine European Countries: Evidence Review and Economic Evaluation","volume":"5","author":"Wex","year":"2013","journal-title":"Clinicoecon Outcomes Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2259","article-title":"Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy","volume":"34","author":"Bellet","year":"2016","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jogoh.2018.03.002","article-title":"Ovarian Suppression Failure During Gnrh Agonist Treatment: A Report of Three Breast Cancer Patients","volume":"47","author":"de Ciantis","year":"2018","journal-title":"J Gynecol Obstet Hum Reprod"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/onco.13722","article-title":"Et al. Measuring Ovarian Escape in Premenopausal Estrogen Receptor-Positive Breast Cancer Patients on Ovarian Suppression Therapy","volume":"25","author":"Burns","year":"2021","journal-title":"Oncologist"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.665426\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T07:53:12Z","timestamp":1619596392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.665426\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,28]]},"references-count":30,"alternative-id":["10.3389\/fonc.2021.665426"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.665426","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,28]]},"article-number":"665426"}}